| Korean Regulatory Post Marketing Surveillance for Somavert (NCT05131100) | Pfizer | 2022-07-13 |
| Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China (NCT05431803) | Ipsen | 2022-06-30 |
| A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (NCT05364944) | Debiopharm International SA | 2022-05-18 |
| A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2) (NCT05192382) | Crinetics Pharmaceuticals Inc. | 2021-12-17 |
| Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery (NCT05149495) | University Hospital, Strasbourg, France | 2021-10-01 |
| A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly (NCT04522180) | Ionis Pharmaceuticals, Inc. | 2021-01-04 |
| The TMS Treatment for Postoperative Headache in GH Tumor (NCT04529356) | Huashan Hospital | 2020-09-01 |
| A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy (NCT04520646) | Huashan Hospital | 2020-09-01 |
| Reproducibility and Utility of OGTT in Acromegaly (NCT04066569) | Assistance Publique - Hôpitaux de Paris | 2020-08-24 |
| PegvisOMant and the Immune SystEm (PROMISE) (NCT05069324) | University of Roma La Sapienza | 2020-07-29 |
| Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly (NCT04003519) | Ipsen | 2020-04-01 |
| A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance) (NCT04261712) | Crinetics Pharmaceuticals Inc. | 2020-01-29 |
| ACRODAT Prospective Evaluation Study (NCT04349839) | University of Aarhus | 2020-01-15 |
| A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly (NCT04125836) | Camurus AB | 2019-10-10 |
| A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly (NCT04076462) | Camurus AB | 2019-08-19 |
| Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands (NCT03967249) | Ionis Pharmaceuticals, Inc. | 2019-07-25 |
| Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study (NCT05964712) | Istituto Auxologico Italiano | 2019-06-18 |
| Vitamin D Metabolism in Patients With Endocrine Disorders (NCT04844164) | Endocrinology Research Centre, Moscow | 2019-04-16 |
| An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge) (NCT03789656) | Crinetics Pharmaceuticals Inc. | 2019-03-12 |
| A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) (NCT03792555) | Crinetics Pharmaceuticals Inc. | 2019-03-11 |
| Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands (NCT03548415) | Ionis Pharmaceuticals, Inc. | 2018-09-13 |
| Olfactory Function and Olfactory Bulb Volume in Acromegaly Patients (NCT04138537) | Bezmialem Vakif University | 2018-08-15 |
| A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers (NCT03571594) | Ono Pharmaceutical Co., Ltd. | 2018-06-07 |
| Muscle in Acromegaly and Cushing's Syndrome (NCT03673761) | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 2018-02-01 |
| The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research (NCT03158090) | Ginkgo Leaf Center for Rare Disorders | 2017-12-15 |
| Acromegaly - Before and After Treatment (NCT03431727) | University of Aarhus | 2017-10-01 |
| Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly (NCT03252353) | Chiasma, Inc. | 2017-09-01 |
| Strict IGF-1 Control in Acromegaly (NCT02952885) | Unity Health Toronto | 2017-07-27 |
| Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly (NCT03045302) | Ipsen | 2017-01-26 |
| Buccodental Manifestations in Patients With Acromegaly (NCT03401008) | University Hospital, Clermont-Ferrand | 2016-12-15 |
| Treatment Patterns and Treatment Outcomes for Acromegaly (NCT03043586) | Columbia University | 2016-12-01 |
| Dynamic Hormone Diagnostics in Endocrine Disease (NCT02934399) | Haukeland University Hospital | 2016-10-01 |
| Bone MicroArchitecture in Acromegaly (NCT03225040) | Columbia University | 2016-08-03 |
| Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects (NCT02807233) | Ipsen | 2016-07-01 |
| Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly (NCT02685709) | Chiasma, Inc. | 2016-02-01 |
| Rehabilitation Program in Patients With Acromegaly (NCT03710499) | Centro Universitário Augusto Motta | 2016-01-10 |
| Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg (NCT02698384) | Ipsen | 2016-01-01 |
| Pasireotide LAR and Pegvisomant Study in Acromegaly (NCT02668172) | Erasmus Medical Center | 2015-08-01 |
| Validation Study of the SAGIT® Instrument in Acromegaly (NCT02539927) | Ipsen | 2015-07-01 |
| Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues (NCT02354508) | Novartis Pharmaceuticals | 2015-03-31 |
| Seoul National University Pituitary Disease Cohort Study (NCT03474601) | Seoul National University Hospital | 2015-03-15 |
| Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly (NCT02396953) | Ipsen | 2015-03-01 |
| Assessment of Airway in Patients With Acromegaly for Predicting Successful Tracheal Intubation (NCT02403414) | All India Institute of Medical Sciences | 2015-03-01 |
| Late Effects of Radiosurgery on Acromegaly Study (NCT02296216) | Assistance Publique Hopitaux De Marseille | 2015-02-16 |
| Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) (NCT02299089) | Camurus AB | 2015-01-01 |
| Cardiac (CMRI) Assessment of Acromegaly (NCT02948322) | Assistance Publique - Hôpitaux de Paris | 2014-12-01 |
| Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly (NCT02493517) | Ipsen | 2014-10-01 |
| Predictive Factors Study (NCT02020499) | Ipsen | 2014-08-01 |
| Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly (NCT02115906) | Medical University of Vienna | 2014-08-01 |
| Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism? (NCT02152124) | University Hospital, Ghent | 2014-06-01 |
| Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly (NCT02060383) | Novartis Pharmaceuticals | 2014-05-23 |
| Phase II Study With ITF2984 in Acromegalic Patients (NCT02111044) | Italfarmaco | 2014-04-01 |
| Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues (NCT02427295) | Asan Medical Center | 2014-03-01 |
| IGF-I and Free Fatty Acids Isn Glucose Metabolism in Acromegaly (NCT02084095) | Carol Davila University of Medicine and Pharmacy | 2014-03-01 |
| Programme of Acromegaly Screening in Patients With Associated Somatic Disorders (NCT02020967) | Ipsen | 2013-12-05 |
| The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics (NCT02217800) | Aspireo Pharmaceuticals Limited | 2013-11-01 |
| Description of Sign-and-symptom Associations at Acromegaly Diagnosis. (NCT02012127) | Ipsen | 2013-09-01 |
| Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly. (NCT02092129) | Rigshospitalet, Denmark | 2013-09-01 |
| Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies (NCT01794793) | RECORDATI GROUP | 2013-06-10 |
| A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. (NCT01861717) | Saint John's Cancer Institute | 2013-05-01 |
| Brain-gut Interaction in Irradiated Patients With Acromegaly (NCT02005978) | Rigshospitalet, Denmark | 2013-04-01 |
| Epidemiology of Acromegaly in Denmark 1991-2010 (NCT01752621) | University of Aarhus | 2013-02-01 |
| SAGIT for Classification of Patients With Acromegaly in Clinical Practice (NCT02231593) | Ipsen | 2013-02-01 |
| Acromegaly Treatment Quality of Life Study (NCT01732406) | Massachusetts General Hospital | 2013-01-01 |
| Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects (NCT01723748) | University of Aarhus | 2012-12-01 |
| Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations in Acromegaly (NCT01902420) | TC Erciyes University | 2012-11-01 |
| Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism (NCT01673646) | Novartis Pharmaceuticals | 2012-10-16 |
| Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients. (NCT02235987) | Aspireo Pharmaceuticals Limited | 2012-10-01 |
| Developing a Simple Recognition System of Acromegaly (NCT03042026) | National Taiwan University Hospital | 2012-06-01 |
| Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target (NCT01618513) | University of Aarhus | 2012-06-01 |
| Somatuline Predictive Factors in Acromegaly and NET (NCT01840449) | Ipsen | 2012-06-01 |
| Prospective Study on Changes in Acromegaly (NCT01612624) | Radboud University Medical Center | 2012-05-01 |
| Acromegaly Combination Treatment Study (NCT01538966) | Cedars-Sinai Medical Center | 2012-03-29 |
| Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly (NCT01412424) | Chiasma, Inc. | 2012-03-01 |
| One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma (NCT01471405) | Ipsen | 2012-01-01 |
| Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors (NCT01568359) | Emory University | 2011-12-01 |
| Rhinological Outcomes in Endonasal Pituitary Surgery (NCT01504399) | St. Joseph's Hospital and Medical Center, Phoenix | 2011-10-01 |
| Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs (NCT01371045) | Cedars-Sinai Medical Center | 2011-06-01 |
| The Observational Study of Growth Hormone-secreting Pituitary Tumors (NCT01368133) | Huashan Hospital | 2011-05-01 |
| Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly (NCT01295060) | Endo USA Inc., a Keenova Therapeutics Company | 2011-02-01 |
| Effect of Growth Hormone (GH) on Cardiac Echos in GH Deficient Patients After Acromegaly Treatment (NCT01302652) | Massachusetts General Hospital | 2011-02-01 |
| Clomiphene Citrate for Treatment of Acromegaly (NCT02274311) | Felipe Henning Gaia Duarte | 2011-01-01 |
| Tissue Biomarker for Pegvisomant Action (NCT01261000) | Cedars-Sinai Medical Center | 2010-11-01 |
| Study in Polish Acromegalic Patients Treated With Somatuline Autogel (NCT01333384) | Ipsen | 2010-10-01 |
| Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly (NCT01137682) | Novartis Pharmaceuticals | 2010-07-19 |
| Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ® (NCT01086982) | Azidus Brasil | 2010-03-01 |
| Peripheral Metabolic Effects of Somatostatin (NCT01062529) | University of Aarhus | 2009-10-01 |
| Surgical Versus Medical Treatment of Acromegaly (NCT01000090) | University of Aarhus | 2009-10-01 |
| Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism. (NCT01265121) | University of Sao Paulo General Hospital | 2009-09-01 |
| Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) (NCT00915954) | Cedars-Sinai Medical Center | 2008-12-01 |
| Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects (NCT00701363) | Ipsen | 2008-10-01 |
| Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly (NCT00765323) | Endo USA Inc., a Keenova Therapeutics Company | 2008-09-01 |
| Non Interventional Post Marketing Programme in Acromegaly (NCT00747500) | Ipsen | 2008-07-01 |
| Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients (NCT00652379) | University of Aarhus | 2008-06-01 |
| Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG) (NCT00517491) | Ipsen | 2008-05-01 |
| Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study (NCT00686348) | Ipsen | 2008-05-01 |
| Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma (NCT00690898) | Ipsen | 2008-05-01 |
| Glucose Tolerance in Acromegaly: The Influence of GH-excess on Glucose Metabolism and Insulin Resistance (NCT00663000) | University Hospital Tuebingen | 2008-04-01 |
| Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients (NCT00642421) | Ambrilia Biopharma, Inc. | 2008-02-01 |
| Substrate Metabolism and Insulin Sensitivity in Acromegalic Patients Before and After Treatment (NCT00647179) | University of Aarhus | 2008-02-01 |